Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
International Journal of Clinical Oncology
Erschienen in: International Journal of Clinical Oncology 8/2021

29.06.2021 | Invited Review Article

Perspectives for circulating tumor DNA in clinical management of colorectal cancer

verfasst von: Ichiro Takemasa, Atsushi Hamabe, Masayuki Ishii

Erschienen in: International Journal of Clinical Oncology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Growing evidence has demonstrated that circulating tumor DNA (ctDNA) detection in colorectal cancer might be a promising approach to address current important clinical questions. During chemotherapy for metastatic colorectal cancer, tumor cells acquire potential resistance by generating additional somatic mutations related to therapeutic resistance. ctDNA can capture the tumor landscape, including heterogeneity, which might provide the opportunity for additional treatment options. Moreover, ctDNA detection is advantageous, because it can monitor tumor heterogeneity serially, in a non-invasive manner. ctDNA is considered valid for detecting minimal residual disease after a curable resection. By utilizing ctDNA detection, adjuvant chemotherapy for patients with stage II–III colorectal cancer might be omitted for patients at low risk of recurrence; or conversely, adjuvant chemotherapy might be highly recommended for patients at high risk, based on ctDNA findings. During multidisciplinary treatments for locally advanced rectal cancer, it is essential to monitor the responses to sequential treatments to make appropriate decisions. Currently, these decisions are mainly based on radiological or pathological findings. ctDNA can add value by providing the real-time status of locally advanced rectal cancer. In this review, we summarized the current evidence and discussed future strategies for using ctDNA in the treatment of colorectal cancer.
Literatur
1.
Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482PubMedCrossRef
2.
Quirke P, Durdey P, Dixon MF et al (1986) Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 2:996–999PubMedCrossRef
3.
4.
5.
Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRef
6.
Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116PubMedCrossRef
7.
Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123PubMedCrossRef
8.
Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef
9.
Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471PubMedCrossRef
10.
Kapiteijn EMC, Nagtegaal ID, Putter H et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646PubMedCrossRef
11.
Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204PubMedCrossRef
12.
Swedish Rectal Cancer T, Cedermark B, Dahlberg M et al (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987CrossRef
13.
Yothers G, O’Connell MJ, Allegra CJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768–3774PubMedPubMedCentralCrossRef
14.
15.
Yamazaki K, Yamanaka T, Shiozawa M et al (2021) Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol 32:77–84PubMedCrossRef
16.
Yoshino T, Yamanaka T, Oki E et al (2019) Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol 5:1574–1581PubMedPubMedCentralCrossRef
17.
Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C et al (2015) Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol 26:644–656PubMedCrossRef
18.
Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799PubMedCrossRef
19.
Fakih MG (2015) Metastatic colorectal cancer: current state and future directions. J Clin Oncol 33:1809–1824PubMedCrossRef
20.
Corcoran RB, Chabner BA (2018) Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med 379:1754–1765PubMedCrossRef
21.
22.
Parseghian CM, Napolitano S, Loree JM et al (2019) Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res 25:6899–6908PubMedPubMedCentralCrossRef
23.
Siena S, Sartore-Bianchi A, Garcia-Carbonero R et al (2018) Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol 29:119–126PubMedCrossRef
24.
Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795–801PubMedPubMedCentralCrossRef
25.
Goodwin S, McPherson JD, McCombie WR (2016) Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet 17:333–351PubMedCrossRef
26.
Morganti S, Tarantino P, Ferraro E et al (2019) Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol 133:171–182PubMedCrossRef
27.
Alves Martins BA, de Bulhoes GF, Cavalcanti IN et al (2019) Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research. Front Oncol 9:1284PubMedPubMedCentralCrossRef
28.
Hata T, Takemasa I, Takahashi H et al (2017) Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. Br J Cancer 117:227–232PubMedPubMedCentralCrossRef
29.
Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224CrossRef
30.
Siravegna G, Marsoni S, Siena S et al (2017) Integrating liquid BIOPSIES into the management of cancer. Nat Rev Clin Oncol 14:531–548PubMedCrossRef
31.
Swarup V, Rajeswari MR (2007) Circulating (cell-free) nucleic acids–a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 581:795–799PubMedCrossRef
32.
Merker JD, Oxnard GR, Compton C et al (2018) Circulating Tumor DNA Analysis in Patients With Cancer: American tSociety of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 36:1631–1641PubMedCrossRef
33.
Siravegna G, Mussolin B, Venesio T et al (2019) How liquid biopsies can change clinical practice in oncology. Ann Oncol 30:1580–1590PubMedCrossRef
34.
Guibert N, Pradines A, Favre G, et al (2020) Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev 29:190052
35.
Mandel P, Metais P (1948) Nuclear acids in human blood plasma. C R Seances Soc Biol Fil 142:241–243PubMed
36.
Janne PA, Borras AM, Kuang Y et al (2006) A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12(3 Pt 1):751–758PubMedCrossRef
37.
Ryan BM, Lefort F, McManus R et al (2003) A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 52:101–108PubMedPubMedCentralCrossRef
38.
Postel M, Roosen A, Laurent-Puig P et al (2018) Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn 18:7–17PubMedCrossRef
39.
Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859–1864PubMedCrossRef
40.
Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337CrossRef
41.
Dienstmann R, Vermeulen L, Guinney J et al (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17:79–92PubMedCrossRef
42.
Fearon ER, Carethers JM (2015) Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 148:10–13PubMedCrossRef
43.
Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81–94PubMedCrossRef
44.
Dasari A, Morris VK, Allegra CJ et al (2020) ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17:757–770PubMedPubMedCentralCrossRef
45.
46.
Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990PubMedCrossRef
47.
Salem ME, Puccini A, Tie J (2020) Redefining colorectal cancer by tumor biology. Am Soc Clin Oncol Educ Book 40:1–13PubMed
48.
49.
Hashiguchi Y, Muro K, Saito Y et al (2019) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42PubMedPubMedCentralCrossRef
50.
51.
Adam R, de Gramont A, Figueras J et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:729–741PubMedCrossRef
52.
Donati M, Stavrou GA, Stang A et al (2015) “Liver-first” approach for metastatic colorectal cancer. Future Oncol 11:1233–1243PubMedCrossRef
53.
Iwai T, Yamada T, Takahashi G et al (2020) Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases. Eur J Surg Oncol 46:108–114PubMedCrossRef
54.
Garlan F, Laurent-Puig P, Sefrioui D et al (2017) Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res 23:5416–5425PubMedCrossRef
55.
Parikh AR, Mojtahed A, Schneider JL et al (2020) Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res 26:1877–1885PubMedPubMedCentralCrossRef
56.
Vidal J, Muinelo L, Dalmases A et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28:1325–1332PubMedPubMedCentralCrossRef
57.
Tie J, Kinde I, Wang Y et al (2015) Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26:1715–1722PubMedPubMedCentralCrossRef
58.
Cremolini C, Rossini D, Dell’Aquila E et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 5:343–350PubMedCrossRef
59.
Santini D, Vincenzi B, Addeo R et al (2012) Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 23:2313–2318PubMedCrossRef
60.
Strickler JH, Loree JM, Ahronian LG et al (2018) Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov 8:164–173PubMedCrossRef
61.
Parseghian CM, Loree JM, Morris VK et al (2019) Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 30:243–249PubMedCrossRef
62.
Montagut C, Tsui DW, Diaz LA Jr (2018) Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use? Ann Oncol 29:1083–1084PubMedCrossRef
63.
Bando H, Kagawa Y, Kato T et al (2019) A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Brit J Cancer 120:982–986PubMedPubMedCentralCrossRef
64.
Meric-Bernstam F, Hurwitz H, Raghav KPS et al (2019) Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20:518–530PubMedPubMedCentralCrossRef
65.
Hainsworth JD, Meric-Bernstam F, Swanton C et al (2018) Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 36:536–542PubMedCrossRef
66.
Sartore-Bianchi A, Trusolino L, Martino C et al (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738–746PubMedCrossRef
67.
Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632–1643PubMedCrossRef
68.
Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282PubMedCrossRef
69.
Nakamura Y, Okamoto W, Kato T et al (2019) TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study. Ann Oncol 30:v199–v200CrossRef
70.
Reinert T, Henriksen TV, Christensen E et al (2019) Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol 5:1124–1131PubMedPubMedCentralCrossRef
71.
Scholer LV, Reinert T, Orntoft MW et al (2017) Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Clin Cancer Res 23:5437–5445PubMedCrossRef
72.
Tie J, Wang Y, Tomasetti C, et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra392
73.
Tarazona N, Gimeno-Valiente F, Gambardella V et al (2019) Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol 30:1804–1812PubMedCrossRef
74.
Tie J, Cohen JD, Wang Y et al (2019) Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 5:1710–1717PubMedPubMedCentralCrossRef
75.
Wang Y, Li L, Cohen JD et al (2019) Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol 5:1118–1123PubMedPubMedCentralCrossRef
76.
Reinert T, Scholer LV, Thomsen R et al (2016) Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65:625–634PubMedCrossRef
77.
Zhang Q, Luo J, Wu S et al (2020) Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 10:1842–1853PubMedCrossRefPubMedCentral
78.
Avanzini S, Kurtz DM, Chabon JJ, et al (2020) A mathematical model of ctDNA shedding predicts tumor detection size. Sci Adv. 6:eabc4308
79.
Newman AM, Bratman SV, To J et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548–554PubMedPubMedCentralCrossRef
80.
Yoshinami T, Kagara N, Motooka D, et al (2020) Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer. Transl Oncol 13:100787
81.
Kagawa Y, Elez E, Garcia-Foncillas J, et al (2021) Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clin Cancer Res. doi: https://​doi.​org/​10.​1158/​1078-0432.​CCR-20-3677. Online ahead of print
82.
83.
Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–717PubMedPubMedCentralCrossRef
84.
Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640PubMedCrossRef
85.
Takemasa I (2020) Advances and controversies in treatment for locally advanced rectal cancer over the past decades: West meets East. Ann Gastroenterol Surg 4:314–315PubMedPubMedCentralCrossRef
86.
Petrelli F, Trevisan F, Cabiddu M et al (2020) Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 271:440–448PubMedCrossRef
87.
Maas M, Lambregts DM, Nelemans PJ et al (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: Selection for Organ-Saving Treatment. Ann Surg Oncol 22:3873–3880PubMedPubMedCentralCrossRef
88.
Weiser MR, Gollub MJ, Saltz LB (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI. Ann Surg Oncol 22:3769–3771PubMedCrossRef
89.
Fusco R, Petrillo M, Granata V et al (2017) Magnetic resonance imaging evaluation in neoadjuvant therapy of locally advanced rectal cancer: a systematic review. Radiol Oncol 51:252–262PubMedPubMedCentralCrossRef
90.
Joye I, Deroose CM, Vandecaveye V et al (2014) The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol 113:158–165PubMedCrossRef
91.
Tie J, Cohen JD, Wang Y et al (2019) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 68:663–671PubMedCrossRef
92.
Zhou J, Wang C, Lin G et al (2020) Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. Clin Cancer Res 27:301–310PubMedCrossRef
93.
Murahashi S, Akiyoshi T, Sano T et al (2020) Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer 123:803–810PubMedPubMedCentralCrossRef
94.
Khakoo S, Carter PD, Brown G et al (2020) MRI tumor regression grade and circulating tumor dna as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res 26:183–192PubMedCrossRef
95.
96.
Chan KC, Jiang P, Zheng YW et al (2013) Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59:211–224PubMedCrossRef
97.
Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112PubMedCrossRef
98.
99.
Kinde I, Wu J, Papadopoulos N et al (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 108:9530–9535PubMedPubMedCentralCrossRef
100.
Diehl F, Li M, He Y et al (2006) BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3:551–559PubMedCrossRef
101.
Hindson BJ, Ness KD, Masquelier DA et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83:8604–8610PubMedPubMedCentralCrossRef
Metadaten
Titel
Perspectives for circulating tumor DNA in clinical management of colorectal cancer
verfasst von
Ichiro Takemasa
Atsushi Hamabe
Masayuki Ishii
Publikationsdatum
29.06.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 8/2021
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-01937-5

Weitere Artikel der Ausgabe 8/2021

International Journal of Clinical Oncology 8/2021 Zur Ausgabe

Original Article

Delayed diagnosis and treatment of children with cancer during the COVID-19 pandemic

Original Article

Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study

Original Article

On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma

Original Article

Clinico-pathological characteristics of patients with stage IB1–IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan

Special Article

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer

Original Article

Long-term results of fluorescence and indigo carmine blue dye-navigated sentinel lymph node biopsy

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise